Trial Profile
A retrospective study to evaluate discontinuation patterns of abiraterone acetate or enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Apr 2016
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 01 Apr 2016 New trial record